Related Experiment Video

Updated: Aug 14, 2026

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat
08:50

5/6th Nephrectomy in Combination with High Salt Diet and Nitric Oxide Synthase Inhibition to Induce Chronic Kidney Disease in the Lewis Rat

Published on: July 3, 2013

ALK5 inhibition in renal disease

Nicholas J Laping1

  • 1GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, PO 1539 King of Prussia, PA 19406, USA. nicholas_j_laping@gsk.com

Current Opinion in Pharmacology
|April 12, 2003
PubMed

Insights

Novel small molecule inhibitors targeting the transforming growth factor-beta (TGF-beta) type I receptor kinase show promise for treating fibrotic diseases. Inhibiting this key signaling pathway may prevent organ remodeling in conditions like chronic renal disease.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Nephrology

Background:

  • Transforming growth factor-beta (TGF-beta) signaling is integral to fibrotic processes.
  • Organ remodeling diseases, including chronic renal disease, are characterized by fibrosis.
  • Targeting TGF-beta offers a potential therapeutic strategy for fibrotic conditions.

Purpose of the Study:

  • To explore novel small molecule inhibitors of the TGF-beta type I receptor kinase.
  • To evaluate the potential of these inhibitors in treating organ remodeling and fibrotic diseases.
  • To investigate the specific benefits of TGF-beta pathway inhibition in renal disease.

Main Methods:

  • Identification of novel small molecule inhibitors.
  • Focus on the TGF-beta type I receptor kinase.
  • Assessment of therapeutic potential in preclinical models (implied).

Main Results:

  • Novel small molecule inhibitors of TGF-beta type I receptor kinase have been identified.
  • These inhibitors represent a potential therapeutic approach for fibrotic diseases.
  • Inhibition of TGF-beta signaling is relevant for preventing fibrosis in renal disease.

Conclusions:

  • Selective inhibition of the TGF-beta signaling pathway is a promising therapeutic strategy.
  • This approach may offer novel treatments for various fibrotic diseases.
  • TGF-beta inhibition could prevent fibrosis, tubular dedifferentiation, and vascular effects in renal disease.

More Related Videos

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells09:40

Isolation, Characterization, And High Throughput Extracellular Flux Analysis of Mouse Primary Renal Tubular Epithelial Cells

Published on: June 20, 2018

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Related Concept Videos

Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa01:22

Renal Drug Excretion: Effect of Urine pH, Flow Rate, and Drug pKa

The pH of urine, the drug's pKa, and the urine flow rate are vital parameters for drug reabsorption and excretion. Urinary pH varies between 4.6 and 8.0 and is influenced by diet, drug intake, and the patient's pathophysiology. It affects a drug's ionization state and reabsorption. For instance, carbohydrate-rich food produces alkaline urine promoting drug excretion, while proteins and certain medications like ascorbic acid lead to acidic urine enhancing reabsorption.
The pKa of a drug,...
Renal Drug Clearance: Overview01:06

Renal Drug Clearance: Overview

Renal clearance is a crucial parameter in pharmacokinetics that quantifies the rate at which the kidneys excrete a drug. It represents a constant fraction of the central volume of distribution containing the drug that the kidney eliminates per unit of time.
Renal clearance can be calculated using different methods. One approach is to divide the urinary drug excretion rate by the plasma drug concentration. This method directly measures renal clearance, indicating the kidneys' efficiency in...
Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...